APPLICATION OF PIOGLITAZONE IN THE COMPREHENSIVE TREATMENT OF PSORIATIC PATIENTS WITH CONCOMITANT ALIMENTARY OBESITY

  • Ya.O. Yemchenko Ukrainian Medical Stomatological Academy, Poltava
  • K.Ye. Ishcheikin Ukrainian Medical Stomatological Academy, Poltava
  • I.P. Kaidashev Ukrainian Medical Stomatological Academy, Poltava
Keywords: psoriasis, alimentary obesity, pathogenesis, clinical presentation, systemic inflammation, treatment.

Abstract

Psoriasis is one of the most common chronic recurrent systemic autoimmune multifactorial diseases, in which the skin, joints, internal organs and systems of the body are involved in the pathological process. Despite the significant prevalence of psoriasis and a large number of studies on this problem, there is still no single view on the pathogenesis of this dermatosis. To objectively understand the pathogenesis of psoriasis, it is necessary to take into account the insufficiently studied comorbidity of this pathology. Recently, an indisputable link between psoriasis and obesity has been proven. The scientific literature widely covers the issue of identical pathogenetic mechanisms of inflammatory processes in psoriasis and obesity. Given the current data on the role of systemic inflammation underlying the development of both psoriasis and obesity, the study of molecular mechanisms of its development and taking into account the role of proinflammatory nuclear transcription factors, thiazolidinediones are the pathogenetically justified drugs of choice for treatment of these diseases. In this study, we determined the effectiveness of using 15 mg of pioglitazone once a day for 6 months in the treatment of patients with extensive psoriasis vulgaris of moderate severity and concomitant grade І-ІІ alimentary obesity by clinical and immunological examination of systemic inflammation. Analyzing the results of the study, it was found that long-term use of pioglitazone, even in small doses, led to a decrease in systemic inflammation and contributed to a milder course of psoriasis in recurrence of the disease.

Downloads

Download data is not yet available.

References

1. Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL et al. Psoriasis - as an autoimmune disease caused by molecular mimicry. Trends Immunol 2015; 30 (10): 494-501.
2. Atkinson RL. Could viruses contribute to the worldwide epidemic of obesity Int J Pediat Obes. 2018; 3: Suppl 1: 37-43.
3. Kaydashev IP. Izmenenie obraza zhizni, narushenie energeticheskogo metabolizma i sistemnoe vospalenie kak faktory razvitiya bolezney civilizacii. Ukraїns'kiy medichniy chasopis. 2013; 5: 103-108. [in Ukrainian]
4. Yemchenko Ya. Riven pokaznykiv systemnoho zapalennia u khvorykh na psoriaz obtiazhenyi metabolichnym syndromom . Zhurnal dermatovenerolohii ta kosmetolohii imeni M .O.Torsueva. 2018; № 1 (38):31-35.
5. Kaydashev IP. NF-kB-signalizaciya kak osnova razvitiya sistemnogo vospaleniya, insulinorezistentnosti, lipotoksichnosti, saharnogo diabeta 2-go tipa i ateroskleroza. Mezhdunarodnyy endokrinologicheskiy zhurnal 2013; 3(35): 35-40.
6. Zhao W, Wu C, Li S, Chen X. Adiponectin protects palmitic acid induced endothelial inflammation and insulin resistance via regulating ROS/IKKβ pathways. Cytokine. 2016; 88:167–176.
7. Schernthaner G. Craig Currie J, Schernthaner G. Do we still need pioglitazone for the treatment of type 2 diabetes. A risk-benefit critique in 2013. Diabetes Care. 2013; 36: 2013-2031.
8. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: National Institutes of Health. 2000, NIH publication 00-4084.
9. Fredriksson, T., U. Pettersson. Severe psoriasis—oral therapy with a new retinoid. Dermatologica. 1978, 157(4):238-44.
10. Mitsui A, Tada Y, Takahashi T, Shibata S, Kamata M. Serum IL‐33 levels are increased in patients with psoriasis. Experimental dermatology. 2015; 3(2):234-239.
11. Bertheloot D, Latz E. HMGB1, IL-1a, IL-33 and S100 proteins: dualfunction alarmins. Cell Mol Immunol. 2017; 14(1):43-64.
12. Suganami T, Tanimoto-Koyama K, Nishida J et al. Role of the Tolllike receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2017; 27: 84-91.
13. Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015; 7 (269):269-274.
14. Brikos C, O´Neill LA. Signaling of toll-like receptors. Handb Exp Pharmacol. 2018; 183: 21-50.
15. Cosmi L, Liotta F, Maggi E. Th17 and non-classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. Int Arch Allergy Immunol. 2014; 164 (3): 171-177.
16. Rasin MS, Rasin SM. Faktory transkripcii v centre sovremennoj biologii i mediciny. Receptory, aktiviruemye proliferatorami peroksisom. Likarska sprava. 2013; 3:280-285.
17. Vinnik NI, Kucenko LA. Effektivnost primeneniya pioglitazona v kompleksnoj terapii bolnyh ishemicheskoj boleznyu serdca na fone metabolicheskogo sindroma. Likarska sprava. 2015; 3(4): 67–73 (Ukrainian).
Published
2020-12-30
How to Cite
Yemchenko, Y., Ishcheikin, K., & Kaidashev, I. (2020). APPLICATION OF PIOGLITAZONE IN THE COMPREHENSIVE TREATMENT OF PSORIATIC PATIENTS WITH CONCOMITANT ALIMENTARY OBESITY. The Medical and Ecological Problems, 24(5-6), 7-10. https://doi.org/10.31718/mep.2020.24.5-6.02